UK-headquartered specialty pharmaceutical company Advanz Pharma today announced it expands its specialty brands portfolio with the signing of the acquisition of global rights of Androcur (cyproterone acetate) from German pharma major Bayer (BAYN: DE).
The transaction is subject to customary regulatory filings and is expected to close in the first quarter of 2024.
Androcur is an anti-androgen therapy. It blocks the actions of male sex hormones (androgens) and reduces the amount of male sex hormones produced by the body. It also serves as a treatment in inoperable carcinoma of the prostate. Androcur is sold in more than 60 markets across Europe, Canada, APAC, MENA, and Latin America
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze